Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C

Overview

Journal Clin Microbiol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2016 Nov 1

PMID 27795306

Citations 4

Authors

Eleanor M Wilson

Elana S Rosenthal

Sarah Kattakuzhy

Lydia Tang

Shyam Kottilil

Affiliations

Soon will be listed here.

Abstract

Directly acting antiviral (DAA) combination therapies for chronic hepatitis C virus (HCV) infection are highly effective, but treatment decisions remain complex. Laboratory testing is important to evaluate a range of viral, host, and pharmacological factors when considering HCV treatment, and patients must be monitored during and after therapy for safety and to assess the viral response. In this review, we discuss the laboratory tests relevant for the treatment of HCV infection in the era of DAA therapy, grouped according to viral and host factors.

Citing Articles

Comprehensive evaluation of the mechanism of human adipose mesenchymal stem cells ameliorating liver fibrosis by transcriptomics and metabolomics analysis.

Ji G, Zhang Z, Wang X, Guo Q, Zhang E, Li C Sci Rep. 2024; 14(1):20035.

PMID: 39198546 PMC: 11358327. DOI: 10.1038/s41598-024-70281-1.

HCV Genotype Distribution of Patients with Chronic Hepatitis C in Istanbul.

Bulut M, Topalca U, Murat A, Teke L, Zengin Canalp H, Ocal M Sisli Etfal Hastan Tıp Bul. 2021; 55(1):86-92.

PMID: 33935541 PMC: 8085459. DOI: 10.14744/SEMB.2020.66990.

VirGenA: a reference-based assembler for variable viral genomes.

Fedonin G, Fantin Y, Favorov A, Shipulin G, Neverov A Brief Bioinform. 2017; 20(1):15-25.

PMID: 28968771 PMC: 6488938. DOI: 10.1093/bib/bbx079.

Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.

Lee R, Kottilil S, Wilson E Hepatol Int. 2016; 11(2):161-170.

PMID: 27928718 DOI: 10.1007/s12072-016-9776-8.

References

Barreiro P, Labarga P, Fernandez-Montero J, Poveda E, de Mendoza C, Sanchez C . Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. J Clin Virol. 2013; 58(2):391-5. DOI: 10.1016/j.jcv.2013.06.031. View

Tang L, Ward H, Kattakuzhy S, Wilson E, Kottilil S . Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. Expert Rev Gastroenterol Hepatol. 2015; 10(1):21-36. DOI: 10.1586/17474124.2016.1119042. View

Bedossa P, Poynard T . An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2):289-93. DOI: 10.1002/hep.510240201. View

Lok A, Gardiner D, Hezode C, Lawitz E, Bourliere M, Everson G . Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014; 60(3):490-9. DOI: 10.1016/j.jhep.2013.10.019. View

Kanwal F, Kramer J, Ilyas J, Duan Z, El-Serag H . HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014; 60(1):98-105. PMC: 4689301. DOI: 10.1002/hep.27095. View

Reichard O, Norkrans G, Fryden A, Braconier J, Sonnerborg A, Weiland O . Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C. Scand J Infect Dis. 1999; 30(5):441-6. DOI: 10.1080/00365549850161395. View

Wyles D, Ruane P, Sulkowski M, Dieterich D, Luetkemeyer A, Morgan T . Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015; 373(8):714-25. DOI: 10.1056/NEJMoa1503153. View

Shiffman M, Suter F, Bacon B, Nelson D, Harley H, Sola R . Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357(2):124-34. DOI: 10.1056/NEJMoa066403. View

Martinot-Peignoux M, Stern C, Maylin S, Ripault M, Boyer N, Leclere L . Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010; 51(4):1122-6. DOI: 10.1002/hep.23444. View

10.

Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A . Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clin Infect Dis. 2015; 62(4):440-447. PMC: 4725378. DOI: 10.1093/cid/civ897. View

11.

Afdhal N . Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y). 2013; 8(9):605-7. PMC: 3594956. View

12.

Afdhal N, Reddy K, Nelson D, Lawitz E, Gordon S, Schiff E . Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370(16):1483-93. DOI: 10.1056/NEJMoa1316366. View

13.

Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C . Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PLoS One. 2015; 10(8):e0134395. PMC: 4552686. DOI: 10.1371/journal.pone.0134395. View

14.

Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M . Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015; 63(3):581-5. DOI: 10.1016/j.jhep.2015.04.023. View

15.

Backus L, Belperio P, Shahoumian T, Loomis T, Mole L . Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther. 2015; 42(5):559-73. DOI: 10.1111/apt.13300. View

16.

Kamal S . Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med. 2014; 6:61-77. PMC: 4075960. DOI: 10.2147/HMER.S41127. View

17.

van der Meer A, Wedemeyer H, Feld J, Hansen B, Manns M, Zeuzem S . Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. J Hepatol. 2013; 60(1):191-6. DOI: 10.1016/j.jhep.2013.07.043. View

18.

Chu T, Kulkarni R, Gane E, Roberts S, Stedman C, Angus P . Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology. 2012; 142(4):790-5. DOI: 10.1053/j.gastro.2011.12.057. View

19.

Hezode C, Asselah T, Reddy K, Hassanein T, Berenguer M, Fleischer-Stepniewska K . Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015; 385(9986):2502-9. DOI: 10.1016/S0140-6736(15)60159-3. View

20.

Liu C, Liang C, Liu C, Lin C, Su T, Yang H . Comparison of Abbott RealTime HCV Genotype II with Versant line probe assay 2.0 for hepatitis C virus genotyping. J Clin Microbiol. 2015; 53(5):1754-7. PMC: 4400777. DOI: 10.1128/JCM.03548-14. View